Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare the effect of Semaglutide and metformin on
weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment
period.
The main question it aims to answer is:
• Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28
week treatment period in obese women with PCOS?
Participants will be divided into 2 groups by chance. In the first group, participants will
be asked to take metformin orally. In the second group, participants will take Semaglutide by
injection under the skin weekly.
The maximum duration of participation for the patients in the trial is 32 weeks.
Researchers will compare the weight reduction, quality of life and individuals' wellbeing
between the two groups.